The Spanish program for rare blood donors

Muñiz‐Díaz, Eduardo; Castro, Ana Laura Rabelo Araújo de; Flores, Elena; Larrea, Luis; Puente, Fernando; Ayape, Marisa; Pérez-Vaquero, Miguel Angel

doi:10.21307/immunohematology-2019-046

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12,13,14 In this study, the presence of the RHCE*Cde/cde (r'r), *Cde/cdE (r'r"), *cDe/cDe(Ro), KEL*K (k-), KEL*KPA (Kpb-) and LU*A (Lub-) in White South Africans matched the findings in Caucasian populations of Italy, Netherlands, America, Spain, Germany and Austria. 15,16,17,18,19 Further, the rare E-Hrb-and E-HrSfound among Black South Africans matched findings in the African American population. 20,21,22 The JS*A,JS*A genotype (Jsb-) was found in three Black South Africans and one Indian donor which is not common in South Africa.…”

Section: Discussionsupporting

confidence: 55%

“…The n of the Yta(Yta-) can be attributed to the small study size or area of India sampled. The Yta-antigen was also identified in Italy, 15 America, 17 Spain, 18 Japan 23 and Canada 25 prompting a decision to expand screening for this rare antigen in South Africa to all race groups.…”

Section: Discussionmentioning

confidence: 99%

“…The GATA mutation identified by the ID CORE XT assay predicts Fy(a-,b-); however, this is not the true rare phenotype, but rather an assay limitation. The genotype GYPB*S, GYPB*S or s-phenotype is currently not listed as a rare type in South Africa as it is not difficult to locate; however, s-is listed on the rare donor files of Spain 18 and Japan. 23 Although the S-s-U-phenotype predicted by the GYPB*deletion is rare in Caucasians and found mainly in African Americans, 17 it was found in one White and one Black donor in the present study.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

et al. 2021

View full text Add to dashboard Cite

Background: Molecular red cell genotyping is devoid of serology limitations such as the scarcity of rare antisera and the possibility of inconclusive results due to biological interferences. Blood incompatibility can result in immune transfusion reactions such as haemolytic transfusion reactions or haemolytic disease of the foetus and newborn.Objective: The study aimed to use molecular red cell genotyping to identify rare blood group donors among South African blood donors.Methods: Red cell genotyping data were extracted retrospectively from the BIDS XT genotyping software in the Immunohaematology Reference Laboratory from January 2015 to August 2016. The ID CORE XT genotyping assay was used to identify the single nucleotide polymorphisms of 10 blood groups system alleles in 150 donors. Associations between the resultant genotypes and predicted phenotypes, ABO group, RhD type, race group and gender were studied.Results: Significant red cell genetic variability was noted among the numerous South African donor genotypes identified in this study. Genotyping further confirmed the presence of at least one of the 16 rare genotypes in 50 donors. Group O Black donors were associated with two rare blood types, while several other rare blood types were found only in White donors, supporting an association between ABO/Rh subtype, race group and rare blood types.Conclusion: Targeted screening of donors for antigen-negative rare blood units for patients should be done to reduce the risk of haemolytic transfusion reactions and haemolytic disease of the foetus and newborn.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 1 , 2 In addition, the scarcity of donors with rare blood types represents a global challenge when compatible red cells with a rare blood phenotype are required for transfusion. 3 , 4 For these reasons, the in vitro generation of RBCs, to supplement the donation system, is nowadays a major focus of research in transfusion medicine.…”

Section: Introductionmentioning

confidence: 99%

“…However, the perspective of insufficient blood supply due to population aging, and the potential risk of transfusion‐transmitted infections remain major concerns 1,2 . In addition, the scarcity of donors with rare blood types represents a global challenge when compatible red cells with a rare blood phenotype are required for transfusion 3,4 . For these reasons, the in vitro generation of RBCs, to supplement the donation system, is nowadays a major focus of research in transfusion medicine.…”

Section: Introductionmentioning

confidence: 99%

ABO gene editing for the conversion of blood type A to universal type O in Rh_null donor‐derived human‐induced pluripotent stem cells

Petazzi

Miquel‐Serra

Huertas

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

The limited availability of red cells with extremely rare blood group phenotypes is one of the global challenges in transfusion medicine that has prompted the search for alternative self‐renewable pluripotent cell sources for the in vitro generation of red cells with rare blood group types. One such phenotype is the Rh null , which lacks all the Rh antigens on the red cell membrane and represents one of the rarest blood types in the world with only a few active blood donors available worldwide. Rh null red cells are critical for the transfusion of immunized patients carrying the same phenotype, besides its utility in the diagnosis of Rh alloimmunization when a high‐prevalence Rh specificity is suspected in a patient or a pregnant woman. In both scenarios, the potential use of human‐induced pluripotent stem cell (hiPSC)‐derived Rh null red cells is also dependent on ABO compatibility. Here, we present a CRISPR/Cas9‐mediated ABO gene edition strategy for the conversion of blood type A to universal type O, which we have applied to an Rh null donor‐derived hiPSC line, originally carrying blood group A. This work provides a paradigmatic example of an approach potentially applicable to other hiPSC lines derived from rare blood donors not carrying blood type O.

show abstract

Estimated prevalence of the Duffy null phenotype Fy (a−b−) among black blood-donors in Southwestern Colombia

Quintero-Santacruz

Elvira

Hurtado

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

The Spanish program for rare blood donors

Cited by 5 publications

References 0 publications

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

ABO gene editing for the conversion of blood type A to universal type O in Rh_null donor‐derived human‐induced pluripotent stem cells

Estimated prevalence of the Duffy null phenotype Fy (a−b−) among black blood-donors in Southwestern Colombia

Contact Info

Product

Resources

About

The Spanish program for rare blood donors

Cited by 5 publications

References 0 publications

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

ABO gene editing for the conversion of blood type A to universal type O in Rhnull donor‐derived human‐induced pluripotent stem cells

Estimated prevalence of the Duffy null phenotype Fy (a−b−) among black blood-donors in Southwestern Colombia

Contact Info

Product

Resources

About

ABO gene editing for the conversion of blood type A to universal type O in Rh_null donor‐derived human‐induced pluripotent stem cells